Compounding pharmacists are committed to helping their patients live healthier, better lives —and key to this is ensuring their patients have continuing access to lawfully prescribed, personalized medications tailored to their individual needs.

PCCA's Matt Martin and Melissa Merrell Rhoads provide an update on the FDA's decision to designate human chorionic gonadotropin (HCG) as a biologic product and what that means for compounders and for PCCA.

PCCA applauds the FDA for their decision and statement about Oxitriptan, which ensures that patients with BH4 deficiency can continue to receive the compounded medications they need.